These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11847949)

  • 1. Pancreatitis associated with simvastatin plus fenofibrate.
    McDonald KB; Garber BG; Perreault MM
    Ann Pharmacother; 2002 Feb; 36(2):275-9. PubMed ID: 11847949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin, fenofibrate, and rhabdomyolysis.
    Jacob SS; Jacob S; Williams C; Deeg MA
    Diabetes Care; 2005 May; 28(5):1258. PubMed ID: 15855605
    [No Abstract]   [Full Text] [Related]  

  • 3. [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].
    Ren JY; Chen H; Luo Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Feb; 33(2):122-6. PubMed ID: 15924805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Rhabdomyolysis secondary to simvastatin and phenofibrate].
    Forcadell-Peris MJ; de Diego-Cabanes C
    Semergen; 2014; 40(4):e91-4. PubMed ID: 24768027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
    Filippatos TD; Elisaf MS
    Expert Opin Pharmacother; 2011 Aug; 12(12):1945-58. PubMed ID: 21736529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis.
    Johnson JL; Loomis IB
    Pharmacotherapy; 2006 Mar; 26(3):414-22. PubMed ID: 16503723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.
    Farnier M; Steinmetz A; Retterstøl K; Császár A
    Clin Ther; 2011 Jan; 33(1):1-12. PubMed ID: 21397769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of alternate-day simvastatin and fenofibrate on mixed hyperlipidemia.
    Kayikçioğlu M; Ozerkan F; Soydan I
    Am J Cardiol; 1999 Apr; 83(7):1135-7, A9. PubMed ID: 10190536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety considerations with fenofibrate/simvastatin combination.
    Filippatos TD; Elisaf MS
    Expert Opin Drug Saf; 2015; 14(9):1481-93. PubMed ID: 26134595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin.
    Lee AJ; Maddix DS
    Ann Pharmacother; 2001 Jan; 35(1):26-31. PubMed ID: 11197581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.
    Farnier M; Retterstøl K; Steinmetz A; Császár A
    Diab Vasc Dis Res; 2012 Jul; 9(3):205-15. PubMed ID: 22228773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of fenofibrate on lymphocyte release of proinflammatory cytokines and systemic inflammation in simvastatin-treated patients with atherosclerosis and early glucose metabolism disturbances.
    Krysiak R; Gdula-Dymek A; Okopien B
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):198-202. PubMed ID: 22935083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micronized fenofibrate: a new fibric acid hypolipidemic agent.
    Guay DR
    Ann Pharmacother; 1999 Oct; 33(10):1083-103. PubMed ID: 10534222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
    Penn R; Williams RX; Guha-Ray DK; Sawyers WG; Braun SL; Rains KT
    Clin Ther; 2006 Jan; 28(1):45-54. PubMed ID: 16490579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine-induced acute pancreatitis.
    Doucette DE; Grenier JP; Robertson PS
    Ann Pharmacother; 2000 Oct; 34(10):1128-31. PubMed ID: 11054978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic interaction between simvastatin and fenofibrate with staggered and simultaneous dosing: Does it matter?
    Winsemius A; Ansquer JC; Olbrich M; van Amsterdam P; Aubonnet P; Beckmann K; Driessen S; van Assche H; Piskol G; Lehnick D; Mihara K
    J Clin Pharmacol; 2014 Sep; 54(9):1038-47. PubMed ID: 24691799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case of acute pancreatitis possibly associated with combined salicylate and simvastatin treatment.
    Antonopoulos S; Mikros S; Kokkoris S; Protopsaltis J; Filioti K; Karamanolis D; Giannoulis G
    JOP; 2005 May; 6(3):264-8. PubMed ID: 15883478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
    Kei A; Tellis C; Liberopoulos E; Tselepis A; Elisaf M
    Cardiovasc Ther; 2014 Aug; 32(4):139-46. PubMed ID: 24618208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antacid-induced acute pancreatitis.
    Nykamp D; Kraus EJ
    Consult Pharm; 2013 Apr; 28(4):247-51. PubMed ID: 23552706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fenofibrate-Induced elevation in serum creatinine.
    Ritter JL; Nabulsi S
    Pharmacotherapy; 2001 Sep; 21(9):1145-9. PubMed ID: 11560205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.